Jan 8, 2026 07:05AM
Jan 8, 2026 07:00AM
Dec 8, 2025 10:34AM
Dec 8, 2025 10:31AM
Dec 1, 2025 07:00AM
Dec 1, 2025 07:00AM
Nov 21, 2025 06:40AM Cullinan Oncology Inc. (CGEM) PT Raised to $26 at H.C. Wainwright
Nov 20, 2025 07:13AM
Nov 20, 2025 07:00AM
Nov 6, 2025 07:00AM
Oct 12, 2025 06:27PM
Sep 9, 2025 05:30AM
Aug 21, 2025 06:35AM
Aug 7, 2025 07:00AM Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Jul 22, 2025 07:01AM
Jul 22, 2025 07:00AM
Jun 1, 2025 08:21AM
May 22, 2025 05:15PM
May 8, 2025 07:00AM
Apr 29, 2025 07:03AM
Apr 29, 2025 07:00AM Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
Apr 23, 2025 10:14AM
Apr 16, 2025 07:00AM
Apr 16, 2025 07:00AM
Feb 27, 2025 07:00AM
Jan 30, 2025 06:39AM
Jan 28, 2025 07:00PM
Nov 7, 2024 07:00AM Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Oct 17, 2024 06:54AM
Oct 16, 2024 07:00AM
Oct 16, 2024 07:00AM
Sep 18, 2024 06:40AM
Sep 18, 2024 06:20AM
Sep 17, 2024 07:00AM
Sep 17, 2024 07:00AM Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Sep 16, 2024 07:08AM
Sep 16, 2024 07:02AM
Sep 16, 2024 07:00AM
Sep 14, 2024 04:15AM
Aug 8, 2024 07:00AM
Jun 3, 2024 05:53AM
Jun 1, 2024 07:00AM Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Mar 14, 2024 07:00AM
Mar 1, 2024 07:00AM
Mar 1, 2024 07:00AM
Aug 10, 2023 07:00AM
Aug 3, 2023 04:15PM
May 11, 2023 04:01PM
Mar 27, 2023 07:02AM Cullinan Oncology (CGEM) Announces FDA Clearance of Investigational NDA for CLN-617
Mar 27, 2023 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All